As Chief Informatics Officer at Q-State Biosciences, Dr. Jean Pierre-Schott leads multiple functions within the company, including information software, informatics, and analytics. He and his team have developed central nervous system computational pipelines and deep analysis tools to extract, classify, and score features from Q-State’s proprietary Optopatch data outputs. Jean-Pierre has a long engineering and scientific career that has been focused on the use of computer vision, image and signal processing, pattern recognition and learning to analyze, understand and classify multi-dimensional data. As Senior Director, Advanced Development at MediSpectra, he and his team developed an FDA PMA approved in vivo, non-contact optical detection device to provide real time diagnostic information and facilitate the early detection of cervical cancer. He also worked at Seno Medical Instrument, developing an imaging system that uses opto-acoustic technology interleaved with ultrasound to generate functional and anatomical images without exposing patients to potentially harmful ionizing radiation or contrast agent to diagnose early stages of breast cancer. Jean-Pierre holds a Master’s degree in Electrical Engineering and completed his Ph.D. at the Massachusetts Institute of Technology.
As Chief Executive Officer of Q-State Biosciences, Matthew Fox is responsible for overseeing the company’s operations, developing the growth strategy, and delivering revenue. Most recently, Matthew co-founded Pairnomix and led the personalized research company as Chief Executive Officer. While at Pairnomix, he helped build the market for personalized research services and grew the brand until it combined with Q-State. Prior to joining Pairnomix, Matthew served as Senior Vice President of Corporate Strategy at Upsher-Smith Laboratories, where he led business intelligence efforts, developed and maintained trade and advocacy partnerships, and sourced new opportunities to expand and grow the business. Prior to that role, Matthew served as a Portfolio Manager at Bank am Bellevue in Zurich, Switzerland, investing in global biotechnology and pharmaceutical companies. He holds a B.A. in Neuroscience and Behavior from Wesleyan University in Middletown, Connecticut.
Jonathan Fleming is currently the Chief Business Officer at Q-State Biosciences, where he is responsible for establishing partnerships that will deliver revenue and further the company’s strategic objectives. Jonathan also serves as the Executive Chairman of QurAlis Inc. and Enclear Therapies, two ALS precision medicine companies that were spun out of Q-State Biosciences, and as a director of several other biotechnology companies, including SQZ Biotech and Continuus Pharmaceuticals. He has been a life science entrepreneur for more than 33 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to his current roles, Jonathan was Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, which raised over $1 billion in early stage capital resulting in 21 IPOs and over 40 M&A transactions. He also co-founded several companies including Synaptic Pharmaceuticals (acquired by Lundbeck), Memory Pharmaceuticals (acquired by Roche), and Hypnion Pharmaceuticals (acquired by Lilly). Jonathan has been a senior lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a course on business strategy for life science managers. He holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor’s degree in Political Science from the University of California, Berkeley.
Dr. Owen McManus
Owen McManus, Ph.D., is a drug discovery scientist with extensive experience in drug discovery, electrophysiology, and technology development. He worked for over twenty years at Merck Research labs where he led basic research teams at multiple discovery stages including target identification and validation, assay development, lead identification and optimization. These teams produced a number of clinical candidate compounds in multiple therapeutic areas. He was also Director of Operations at the Johns Hopkins Ion Channel Center, which provided HTS screening and lead optimization for ion channel and transporter targets for the academic community through the NIH Molecular Libraries program. He also worked as Director, Ion Channel Screening and Drug Discovery at Essen Bioscience, a leading instrument development company. At both Essen and Merck, he worked on development of novel instrumentation and technologies to support drug discovery, which have led to several marketed products. He is currently Chief Technology Officer at Q-State Biosciences working to advance Q-State technologies in drug discovery efforts.
Dr. Jean-Pierre Schott
Dr. Graham Dempsey
Graham Dempsey, Ph.D., leads Q-State’s research and development efforts. In this role, he oversees all internal development work and ensures successful execution of Q-State’s partnered programs with pharmaceutical companies and foundations. Graham began his scientific career at the University of Pennsylvania, developing novel single molecule methods for high sensitivity fluorescence measurements of molecular function. He then joined Harvard University where he developed a new super-resolution imaging technique called stochastic optical reconstruction microscopy (STORM), allowing for multicolor, live-cell fluorescence imaging of biological samples with nanometer spatial resolution. The technique was commercialized by Nikon Instruments. Graham received a B.A. in Biochemistry and Physics from the University of Pennsylvania and a Ph.D. in Biophysics from Harvard University.
Dr. David Gerber
Dr. David Gerber currently serves as the Head of Scientific Affairs at Q-State and brings twenty years of experience in CNS disease biology and drug discovery to the company. Prior to joining Q-State, David was scientific co-founder and Vice President of Research at Galenea Corp., where he led discovery programs in schizophrenia, cognition and neurodegeneration, including several R&D collaborations with major pharmaceutical companies. A key aspect of this work included development and application of novel platform technology to directly target synaptic transmission for CNS drug discovery. Before founding Galenea, as a postdoctoral fellow and Research Scientist in Susumu Tonegawa’s lab at MIT, his research focused on molecular and genetic factors involved in schizophrenia, and particularly on the potential link between calcineurin dysfunction and schizophrenia pathogenesis. David received a bachelor’s degree in mathematics and a Ph.D. in biology from the Massachusetts Institute of Technology.
Dr. Chani Maher
As Head of Precision Medicine Services, Dr. Chani Maher leads many operating aspects of Q-State’s precision medicine service offerings. Her responsibilities include managing teams of sales, marketing, and advocacy professionals to drive new business to the company, and coordinating with Q-State scientists to ensure timely deliverables. Chani also regularly liaises with Q-State’s executive leadership to inform precision medicine services strategy. Previously, Chani served as Director of Business Operations at Pairnomix until the company merged with Q-State. In this role, she drove the day-to-day operating activities of Pairnomix and provided managerial oversight to the company’s functions and employees. Chani earned a Ph.D. in Neuroscience and an M.B.A. from the University of Minnesota, as well as a B.S. in Biomedical Sciences and a B.A. in Psychology from SUNY-Buffalo.
Mette Smedegaard Andersen
Mette Smedegaard Andersen joins Q-State from The Boston Consulting Group, where she was a Core Member of the Healthcare practice. Her work there centered on strategy development for Pharma and Biotech, ranging from R&D to drug launch and innovation strategies in companies across the US and Europe. Mette holds an M.B.A. from the Harvard Business School, a MPhil in Nanotechnology from the University of Cambridge, and a B.A. in Chemistry and Physics from Harvard University. While at Harvard Business School, she studied business model innovations for precision medicine.
Emily Pettycrew serves as Q-State’s Head of Finance and is responsible for managing the company’s accounting, treasury, reporting, and budgeting activities. Emily has several years of experience in financial leadership and most recently served as Controller at Chartboost, a venture-backed technology startup based in San Francisco. Prior to this role, Emily held a Finance Manager position at Hercules Capital, a Business Development Company focused on venture lending. She started her accounting career in Assurance at PwC. A Certified Public Accountant, Emily received a Bachelor’s degree from the University of Arizona and an M.B.A from Mills College.
Denise Johnson leads all human resources functions at Q-State. She has over 20 years of experience in a variety of areas, including developing HR processes and policies, compliance, employee relations, performance management, recruiting, benefits, compensation and training. Denise began her career at PriceWaterhouse (PwC) and KPMG, LLC. She then worked for 10 years as a consultant to early stage technology companies. She has held management and consulting positions with emerging growth companies in various industries including software, financial services, and life science organizations. Prior to joining Q-State, Denise established the HR infrastructure for Correlagen Diagnostics, Inc., a leading developer of genetic testing that assists physicians with early diagnosis for a more precise and tailored treatment. Denise earned her B.A. in English Literature with an advanced certificate in Human Resource Management from Northeastern University and is a member of the Society for Human Resource Management.
Dr. Luis Williams
As Head of Cell Biology at Q-State, Dr. Luis Williams leads a team of scientists to develop and execute protocols, including neuronal differentiation and the use of gene editing technology, for the purpose of creating various types of neuronal cellular models. He also oversees his team’s efforts to functionally characterize these models using various proprietary Q-State technologies. Prior to joining Q-State, Luis worked in the laboratory of Q-State co-founder Dr. Kevin Eggan, where he developed models of various nervous system disorders. Luis holds a B.S. in biology from the Universidad Nacional Autónoma de Nicaragua, an M.S. in molecular genetics from the University of California-Davis, and a Ph.D. in stem cell biology from Harvard University.
Dr. Steven Nagle
As Head of Engineering and Production, Dr. Steven Nagle provides management and technical oversight for Q-State engineering, including the development of new instrumentation and assays. He also manages the execution of Q-State’s proprietary Optopatch technology platform. Steven has more than 15 years of engineering experience and served in leadership roles at a variety of ground-breaking technology companies, with nearly a decade focused on micro- and nano-scale device design and fabrication. At Axsun Technologies, he developed the heart of a miniature spectrometer under ISO9001 quality control. At Bruker AXS, he established operations at their nanofabrication center and created original versions of several atomic force microscopy (AFM) probes. These probes make biological AFM measurements easier and faster and enable videos of biological processes at nano-scale resolution. Steven served as an Instructor of Biological Engineering at the Massachusetts Institute of Technology and is currently a Visiting Engineer at the institute. He earned his Ph.D. in electrical engineering from the Massachusetts Institute of Technology where he created the world’s first micro-scale electrostatic induction motor. He earned his Bachelor’s and Master’s degrees through the Integrated Undergraduate Graduate program of the Schreyer Honors College at Penn State.
Dr. Amy Elder
Dr. Amy Elder serves as Q-State’s Director of Chemistry. In this role, Amy manages many of the company’s drug discovery and development efforts. She oversees medicinal chemistry efforts, including the selection of compounds for use in drug screening studies, the analysis of drug screening data, and the selection of lead candidate therapies for further internal or partnered analysis and development. Amy has previously worked for a variety of drug discovery companies. Most recently, she served as Director of Chemistry at Galenea in the CNS area. Prior to this role, she worked at Millennium Pharmaceuticals (now Takeda Oncology) in inflammation and oncology and at Pfizer in the CNS area. Amy has a Ph.D. in organic chemistry from the University of Wisconsin-Madison.
Dr. Kit Werley
As Head of Engineering Research at Q-State, Dr. Kit Werley is responsible for developing new instrumentation and optical assays to probe neuronal excitability and synaptic signaling, which are used for disease modeling and phenotypic drug screening at high throughput. Previously, during his postdoc at Harvard University in the laboratory of Q-State co-founder Dr. Adam Cohen, Kit developed the prototype for Q-State’s Firefly microscope, the workhorse instrument at Q-State. He received his Ph.D. in the field of ultrafast optics from the chemistry department at MIT and his Bachelor’s in chemistry from Stanford University.
Dr. Eric White
Eric White is Head of Genomic Assay Development at QnA Dx, a subsidiary of Q-State Biosciences offering genetic sequencing and interpretation services as part of the Q-State precision medicine services platform. Eric is responsible for designing and validating all genetic sequencing tests offered through QnA Dx. He also supports the company’s efforts to source and evaluate new genomic technologies that could further enhance the company’s sequencing and variant interpretation capabilities. Eric has more than 15 years of experience in genomic assay development. Most recently, he served as Director of Assay and Technology Development at Claritas Genomics. He also held Associate Director and Staff Scientist positions at Thermo Fisher Scientific. In these roles, he helped optimize the company’s Ion Torrent PGM and Proton next-generation sequencing platforms. Eric holds a Ph.D. in microbiology and molecular genetics from the University of Medicine and Dentistry of New Jersey and completed his postdoctoral work at Yale University.
Erika Whyte currently serves as Head of Laboratory Operations at Q-State. In this role, she manages many day-to-day functions at Q-State to ensure the company’s research projects and scientific teams are resourced and supported appropriately. Erika brings significant laboratory operations and management experience to Q-State. She began her career as a social worker managing residential programs and later held several operational and project management roles at a variety of health and biotechnology companies, including ReproSource Inc., Batavia Bioservices, and NovoBiotic Pharmaceuticals. Erika holds a Human Resources Management Certification from the University of Massachusetts.